With the U.S. Food and Drug Administration’s (FDA) recent approval of CAR-T cell therapy, interest in this technology is exponentially growing. For example, why do we need standards for the provision for immune effector cell therapy and what should those standards be? We know about the short term toxicities of this therapy, but what are longer-term complications of CAR-T cell therapy, and what should the referring hematologist know about these patients when they return home? And what do we know about the financial toxicity of offering these therapies to health systems?
There are at least 130 abstracts investigating CAR-T cell therapy at the 2017 ASH Annual Meeting. This special session looks at the modality from a slightly different aspect than the typical presentations at this meeting and will allow the speakers and audience to have a dialogue about issues regarding this exciting and promising therapy.
Elizabeth J. Shpall
Shannon L Maude
Samuel M. Silver
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members